Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, with total revenue reaching 488 million yuan, a year-on-year increase of 28.27% [1] - The net profit attributable to shareholders was 114 million yuan, up 44.85% year-on-year, while the net profit excluding non-recurring items was 106 million yuan, reflecting a 61.09% increase [1] - In Q2 2025, the company achieved a quarterly revenue of 258 million yuan, marking a 62.85% year-on-year growth, and a net profit of approximately 56.4 million yuan, which is a 136.7% increase compared to the same period last year [1] Financial Performance - The company's gross profit margin stood at 67.09%, showing a decrease of 6.20% year-on-year [7] - The return on equity (ROE) was reported at 3.98%, an increase of 46.86% year-on-year [7] - Earnings per share (EPS) reached 0.30 yuan, reflecting a year-on-year increase of 42.85% [7] - Operating cash flow per share was 0.37 yuan, a substantial increase of 304.88% year-on-year [7] Shareholder Information - The top shareholders include Shi Chunbao with a 31.34% stake and Yue Shujun with a 24.88% stake, both of whom are new entrants [11] - Other notable shareholders include Beijing Panmao Investment Management Co., Ltd. and various investment funds, indicating a diverse shareholder base [12]

Summary of Key Points Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management to enhance fund efficiency while ensuring the safety of the funds and not affecting ongoing projects or daily operations [1][10]. Group 1: Fundraising and Management - The company raised a total of RMB 1,145.54 million through the issuance of 38,428,000 shares at a price of RMB 29.81 per share, with a net amount of RMB 1,067.13 million after deducting issuance costs [1][3]. - As of June 30, 2025, the total amount invested in fundraising projects was RMB 504.97 million, with RMB 570 million allocated for cash management, leaving a balance of RMB 53.82 million in the fundraising account [2][3]. Group 2: Cash Management Plan - The company aims to use up to RMB 700 million of idle funds for cash management, with a rolling usage period of 12 months from the board's approval date [5][10]. - The investment products will include low-risk, high-liquidity options such as structured deposits, time deposits, and large certificates of deposit, ensuring that these funds are not used for pledging or securities investment [5][9]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not impact the normal operation of fundraising projects or the company's production activities [10][11]. - The sponsor, Huatai United Securities, has conducted a review and found that the cash management plan complies with relevant regulations and does not harm the interests of shareholders, particularly minority shareholders [11].

报告期内，公司实现归属于母公司股东的净利润约人民币1.14亿元，同比增长44.85%，主要系报告期内 公司稳定供应集采产品、深度拓展国际市场，推动销量增长；同时内部节本增效，强化核心业务竞争 力，内外并举推动盈利能力稳步提升，实现了净利润的持续增长。 格隆汇8月29日丨春立医疗(01858.HK)发布公告，截至2025年6月30日止六个月，公司的营业收入为约人 民币4.88亿元，同比增长28.27%，主要系报告期内稳定供应集采产品，销量持续增长。另外公司稳步推 进国际市场的深度开拓工作，出口业务持续攀升所致。 ...

Core Viewpoint - Spring Medical (01858.HK) reported a significant increase in revenue and net profit for the first half of 2025, driven by stable supply of centralized procurement products and expansion into international markets [1] Financial Performance - The company's operating revenue reached RMB 488 million, representing a year-on-year growth of 28.27% [1] - Total profit, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses for the first half of 2025 were RMB 127 million, RMB 114 million, and RMB 106 million, respectively, with year-on-year growth rates of 53.26%, 44.85%, and 61.09% [1] Strategic Initiatives - The company has made comprehensive and in-depth strategic layouts in the high-value orthopedic consumables sector [1] - There is an active effort to expand into related orthopedic fields, seeking advanced technologies and quality products to enrich the product portfolio [1] - The company aims to increase its market share through a series of initiatives, targeting long-term, stable, and sustainable development in the medical field [1]

Core Viewpoint - Spring Medical (01858) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and market expansion efforts [1] Financial Performance - The company's revenue reached approximately 488 million yuan, representing a year-on-year growth of 28.27% [1] - The net profit attributable to shareholders was about 114 million yuan, showing a year-on-year increase of 44.85% [1] - Basic earnings per share stood at 0.3 yuan [1] Growth Drivers - Revenue growth was primarily driven by stable supply of centralized procurement products and continuous increase in sales volume during the reporting period [1] - The company has been steadily advancing its international market expansion, leading to a rise in export business [1] - Net profit growth was supported by stable supply of centralized procurement products, deepening international market penetration, and internal cost reduction and efficiency enhancement [1]

Core Viewpoint - Spring Medical (01858) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and market expansion efforts [1] Financial Performance - The company's revenue reached approximately 488 million yuan, representing a year-on-year growth of 28.27% [1] - Net profit attributable to shareholders was about 114 million yuan, showing a year-on-year increase of 44.85% [1] - Basic earnings per share stood at 0.3 yuan [1] Revenue Growth Drivers - Revenue growth was primarily driven by stable supply of centralized procurement products and continuous increase in sales volume during the reporting period [1] - The company has been steadily advancing its international market expansion, leading to a rise in export business [1] Profitability Improvement - The increase in net profit was attributed to stable supply of centralized procurement products and deepening international market expansion, which boosted sales [1] - Internal cost reduction and efficiency enhancement measures were implemented to strengthen core business competitiveness, contributing to steady improvement in profitability [1]

每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 （记者 张喜威） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，春立医疗（SH 688236，收盘价：22.35元）8月29日晚间发布公告称，2025年1~6月，公司 计提信用减值损失和资产减值损失合计人民币约3933万元，对报表利润总额影响数约为3933万元。本次 计提信用减值损失和资产减值损失数据未经审计，最终以会计师事务所年度审计确认的金额为准。 2024年1至12月份，春立医疗的营业收入构成为：医疗器械制造占比99.92%，其他业务占比0.08%。 截至发稿，春立医疗市值为86亿元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 截至2025年6月30日止六個月的中期業績公告 北京市春立正達醫療器械股份有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公 司及其附屬公司（「本集團」）截至2025年6月30日止六個月的未經審核合併業績。有關 業績乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）的適用披露規定及 中華人民共和國（「中國」）會計準則而編製。 * 僅供識別 – 1 – 本集團的合併資產負債表 | | | 於2025年 | 於2024年 | | --- | --- | --- | --- | | | 附註 | 6月30日 | 12月31 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司第五屆監事會第十八次會議決議公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年8月29日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供 ...

（ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* * 僅供識別 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司2025年半年度報告摘要》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年8月29日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 北 ...